Microbot Medical announces it has received Institutional Review Board, IRB, approval and signed a clinical trial agreement with Memorial Sloan Kettering Cancer Center, located in New York City, New York. Memorial Sloan Kettering Cancer Center will conduct the clinical trial as part of the Investigational Device Exemption for LIBERTY, and the Company expects its results will support the future marketing submission to the FDA and subsequent commercialization. “We are excited to have a hospital the caliber of Memorial Sloan Kettering Cancer Center partnering with us to complete the enrollment of the clinical sites in our trial,” commented Harel Gadot, CEO, President and Chairman of Microbot Medical.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBOT:
- Microbot Medical Marks Clinical Milestone, Eyes FDA Submission
- Microbot Medical Continues to Ramp Up Patient Enrollment in its Pivotal Human Clinical Trial
- Microbot announces Baptist Hospital completed first procedure using LIBERTY
- Microbot Medical Advances with LIBERTY® System Clinical Trial
- Microbot Medical Enrolled the First Patient in its Pivotal Human Clinical Trial